Extended Dosing Improves Safety of IkT-148009, Animal Studies Show

The safety profile of IkT-148009, an investigational oral medication for Parkinson’s disease, improved the longer the drug was dosed, demonstrating target selectivity, according to interim three-month animal data. The ongoing toxicology studies, conducted by the therapy’s developer, Inhibikase Therapeutics, were designed to meet regulatory requirements for regular…

Inhibikase Cleared to Expand Phase 1 IkT-148009 Study

Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the agency reviewed the safety, tolerability and pharmacokinetic data from a Phase 1 study…

Dosing Begins in Early Trial of Oral Therapy to Protect Dopaminergic Neurons

Dosing has begun in a Phase 1 clinical trial testing Inhibikase Therapeutics’ investigational oral therapy IkT-148009 for Parkinson’s disease and related disorders in healthy volunteers. This first clinical trial (NCT04350177) is expected to enroll 112 healthy adults, ages 45 to 70, at a single site in…